The investigational therapy fenebrutinib was as effective as Ocrevus for reducing disability progression in people with PPMS, a trial showed.

Roche Holdings AG RHHBY on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational ...

Roche's experimental drug fenebrutinib achieved significant results in a Phase III trial for primary progressive multiple sclerosis (PPMS), reducing the risk of disability progression by 12%. This ...

President Donald Trump has said investigators are close to solving the kidnapping of Nancy Guthrie, the mother of Today show ...

Every morning, Josphat Kerongo settles onto a low wooden stool outside his small shop at Mwalimu Plaza in Kisii town, carefully arranging phone accessories and wristwatches within easy reach.Dressed ...

More than two million Americans will suffer a traumatic brain injury in 2026. TBI is one of the leading causes of death and ...

Actor turned rare disease advocate Luke Rosen tells how his daughter, Susannah, lives with a KIF1A-associated neurological ...

A new drug developed by Australian researchers has shown promising results in reducing sepsis in a Phase II clinical trial involving 180 patients. The carbohydrate-based treatment works by calming a ...

Cerebral palsy represents one of the clearest opportunities in modern medicine to reduce lifelong disability, control ...

For millions of people living with major depressive disorder, finding an effective treatment can feel like a never-ending process of trial and error — with no guarantee of ...

Novartis (NVS) announced on Friday that the U.S. Food and Drug Administration (FDA) granted its Breakthrough Therapy designation for ianalumab, its experimental therapy for a multi-organ autoimmune ...

Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can ...